Bessemer Group Inc. Sells 6,047 Shares of United Therapeutics Corporation (NASDAQ:UTHR)

Bessemer Group Inc. trimmed its position in United Therapeutics Corporation (NASDAQ:UTHR - Free Report) by 67.8% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,866 shares of the biotechnology company's stock after selling 6,047 shares during the quarter. Bessemer Group Inc.'s holdings in United Therapeutics were worth $884,000 at the end of the most recent quarter.

Other institutional investors have also made changes to their positions in the company. Cerity Partners LLC lifted its position in shares of United Therapeutics by 30.4% in the 4th quarter. Cerity Partners LLC now owns 11,588 shares of the biotechnology company's stock valued at $4,098,000 after acquiring an additional 2,702 shares in the last quarter. Korea Investment CORP lifted its holdings in shares of United Therapeutics by 6.2% in the fourth quarter. Korea Investment CORP now owns 39,289 shares of the biotechnology company's stock valued at $13,863,000 after purchasing an additional 2,300 shares in the last quarter. Nepsis Inc. lifted its holdings in shares of United Therapeutics by 6.7% in the first quarter. Nepsis Inc. now owns 58,574 shares of the biotechnology company's stock valued at $18,057,000 after purchasing an additional 3,653 shares in the last quarter. ExodusPoint Capital Management LP acquired a new stake in shares of United Therapeutics in the fourth quarter worth $1,899,000. Finally, Raymond James Financial Inc. purchased a new position in shares of United Therapeutics during the fourth quarter valued at $18,257,000. 94.08% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at United Therapeutics

In other news, CFO James Edgemond sold 12,000 shares of the firm's stock in a transaction on Monday, June 9th. The stock was sold at an average price of $325.37, for a total value of $3,904,440.00. Following the transaction, the chief financial officer directly owned 8,118 shares in the company, valued at $2,641,353.66. This trade represents a 59.65% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Paul A. Mahon sold 11,000 shares of United Therapeutics stock in a transaction on Thursday, June 26th. The stock was sold at an average price of $285.70, for a total value of $3,142,700.00. Following the sale, the executive vice president directly owned 36,781 shares of the company's stock, valued at approximately $10,508,331.70. This trade represents a 23.02% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 80,681 shares of company stock valued at $23,951,939. 10.30% of the stock is currently owned by company insiders.

United Therapeutics Trading Down 0.2%

Shares of United Therapeutics stock traded down $0.65 during trading on Thursday, reaching $294.57. The company's stock had a trading volume of 284,123 shares, compared to its average volume of 445,045. United Therapeutics Corporation has a one year low of $266.98 and a one year high of $417.82. The stock has a 50-day moving average price of $301.18 and a two-hundred day moving average price of $323.65. The stock has a market capitalization of $13.29 billion, a P/E ratio of 11.75, a price-to-earnings-growth ratio of 6.37 and a beta of 0.53.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last released its earnings results on Wednesday, April 30th. The biotechnology company reported $6.63 EPS for the quarter, beating the consensus estimate of $6.29 by $0.34. United Therapeutics had a return on equity of 19.33% and a net margin of 40.44%. The company had revenue of $794.40 million during the quarter, compared to analysts' expectations of $726.82 million. During the same period last year, the firm earned $6.17 EPS. The business's revenue for the quarter was up 17.2% on a year-over-year basis. As a group, sell-side analysts anticipate that United Therapeutics Corporation will post 24.48 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

UTHR has been the subject of several research analyst reports. UBS Group reduced their price objective on United Therapeutics from $410.00 to $385.00 and set a "buy" rating for the company in a research note on Monday. Wells Fargo & Company reiterated an "equal weight" rating and issued a $314.00 target price (down previously from $395.00) on shares of United Therapeutics in a report on Friday, April 25th. JPMorgan Chase & Co. decreased their price target on shares of United Therapeutics from $355.00 to $350.00 and set an "overweight" rating for the company in a report on Thursday, May 1st. Cantor Fitzgerald assumed coverage on shares of United Therapeutics in a research report on Monday, June 2nd. They set an "overweight" rating and a $405.00 price objective on the stock. Finally, HC Wainwright reiterated a "buy" rating and issued a $425.00 target price on shares of United Therapeutics in a research report on Monday, May 5th. Four research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. According to MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $386.15.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.